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ABSTRACT Fibronectin (FN) is a critical regulator of extracellular matrix (ECM) remodeling
through its availability and stepwise polymerization for fibrillogenesis. Availability of FN is
regulated by its synthesis and turnover, and fibrillogenesis is a multistep, integrin-dependent
process essential for cell migration, proliferation, and tissue function. Transforming growth
factor β (TGF-β) is an established regulator of ECM remodeling via transcriptional control of
ECM proteins. Here we show that TGF-β, through increased FN trafficking in a transcriptionand SMAD-independent manner, is a direct and rapid inducer of the fibrillogenesis required
for TGF-β–induced cell migration. Whereas TGF-β signaling is dispensable for rapid fibrillogenesis, stable interactions between the cytoplasmic domain of the type II TGF-β receptor
(TβRII) and the FN receptor (α5β1 integrin) are required. We find that, in response to TGF-β,
cell surface–internalized FN is not degraded by the lysosome but instead undergoes recycling
and incorporation into fibrils, a process dependent on TβRII. These findings are the first to
show direct use of trafficked and recycled FN for fibrillogenesis, with a striking role for TGF-β
in this process. Given the significant physiological consequences associated with FN availability and polymerization, our findings provide new insights into the regulation of fibrillogenesis for cellular homeostasis.
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INTRODUCTION
The extracellular matrix (ECM) is a key player in regulating cell differentiation, growth, and motility during wound-healing and fiThis article was published online ahead of print in MBoC in Press (http://www
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brotic responses. Growth factors, particularly transforming growth
factor β (TGF-β), can regulate the ECM by increasing fibronectin
(FN) synthesis (Ignotz and Massague, 1986; Allen-Hoffmann et al.,
1988; Roberts et al., 1988; Bortell et al., 1994; Hocevar and Howe,
2000; Biname et al., 2008). The bulk of TGF-β transcriptional responses, including FN transcription, are mediated through phosphorylation-dependent activation of the type I receptor (TβRI/
ALK5) and SMAD2/3 or SMAD1/5 (Ignotz and Massague, 1986; de
Caestecker, 2004; Daly et al., 2008), which requires the constitutive kinase activity of the type II receptor (TβRII; Massague et al.,
1991).
FN produced by the cell can be assembled in a stepwise manner
by most cell types to produce matrix-associated FN in a process
termed fibrillogenesis (Mao and Schwarzbauer, 2005). In addition to
providing a structural scaffold, fibrillogenesis is key to physiological
cell repair, motility, and adhesion, thus making it a highly regulated
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process affected by the availability of FN, activation state of the FN
receptor, and rate of remodeling (Schwarzbauer and Sechler, 1999;
Schwarzbauer and DeSimone, 2011). Availability and balance of
soluble and matrix-incorporated FN are also critical because soluble
or dimeric FN can drive the epithelial-to-mesenchymal transition,
whereas matrix-associated polymeric FN can decrease cancer cell
invasiveness (Ruoslahti, 1984; Saulnier et al., 1996; Shi et al., 2014).
Such opposing functions point to the significance of soluble versus
matrix FN regulation.
Several studies have examined the molecular requirements and
dynamic nature of fibrillogenesis and its biomechanical properties
(Erickson et al., 1981; Erickson and Carrell, 1983; Lotz et al., 1989;
Danen et al., 2002; Mao and Schwarzbauer, 2005). Initiation and
completion of fibrillogenesis are not always very efficient processes
because a significant portion of FN that is engaged with its receptor
might not be used/incorporated into fibrils (Pankov et al., 2000).
However, once incorporated, remodeling of matrix-incorporated FN
can also occur at the level of protein turnover via either endocytosisdependent lysosomal degradation of FN (Sottile and Chandler,
2005) or during changes in spatiotemporal control of fibrillogenesis.
Such remodeling events determine cellular responses, as seen in
epithelial branching morphogenesis, in which both synthesis and
transient assembly of FN are observed at cleft-forming sites (Sakai
et al., 2003).
Integrins play key roles in fibrillogenesis: α5β1, α8β1, αvβ1,
αvβ3, αIIbβ3, αvβ5, αvβ6, and αvβ8 all recognize the common integrin-binding motif Arg-Gly-Asp (RGD), which is found in many
ECM components, including FN (Danen and Sonnenberg, 2003).
α5β1, however, is most efficient in mediating FN matrix assembly,
with compensation from other integrins also possible in the absence of α5β1 (Wu et al., 1996; Yang and Hynes, 1996). We and
others have also reported several interactions between the TGF-β
and integrin pathways that occur through SMAD-independent
mechanisms and can affect integrin signaling (Hocevar et al., 1999;
Bhowmick et al., 2001; Galliher and Schiemann, 2006, 2007;
Galliher-Beckley and Schiemann, 2008; Garamszegi et al., 2010;
Huck et al., 2010; Mythreye et al., 2013).
Whereas prior studies examined mechanisms of FN turnover
and suggested specific trafficking regulation of ECM components as a mechanism for increased matrix assembly (Abraham
et al., 2004; Sottile and Chandler, 2005; Unlu et al., 2014),
whether non–matrix-incorporated, soluble ECM components
are capable of returning to the cell surface has yet to be determined. Here we show that a rapid fibrillogenesis response to
TGF-β in both nonmotile and motile cells precedes transcriptionally induced fibrillogenesis. We find that one mechanism for
this nontranscriptional fibrillogenesis is via increased FN uptake
and recycling of soluble FN. Our results reveal that internalized
FN can recycle through a Rab11-dependent mechanism for fibrillogenesis, particularly in response to TGF-β stimulation. Of
note, recycled and trafficked FN can constitute a significant portion of matrix-incorporated FN. We also find that TGF-β–induced rapid fibrillogenesis is largely independent of SMAD activation but requires TβRII to mediate FN recycling. Specifically,
we show that this process occurs through a TβRII-α5β1–dependent interaction that is disrupted in the TβRII mutant lacking the
cytoplasmic domain required for trafficking. From a broad perspective, our findings suggest that discrete sources of soluble
FN could be used to build and assemble a FN matrix, which may
directly affect growth factor–regulated matrix assembly and, ultimately, the rate and extent of cell differentiation, growth, and
motility.
1196 | A. Varadaraj et al.

RESULTS
TGF-β1 and TGF-β2 rapidly increase fibrillogenesis
To investigate the effects of TGF-β on FN fibrillogenesis, we used
two approaches: biochemical fractionation of soluble (S) FN and the
fibril-associated insoluble pellet (P) FN using the detergent deoxycholate (DOC fractionation; Sechler et al., 1996) and immunofluorescence microscopy to visualize FN localization and fibrillogenesis.
Using these methods in human foreskin fibroblast cells (HFFs), an
established cell line for FN matrix assembly (Clark et al., 2005), we
find that, in response to a 30-min TGF-β treatment, soluble (S) FN
levels decreased, with a compensatory increase in (P) FN levels
(Figure 1A). Immunolabeling of FN also revealed an increase in the
appearance of FN fibrils in response to both TGF-β1 and TGF-β2
(Figure 1B), in accordance with the biochemical fractionation (Figure
1A). Consistent with the effect of TGF-β in HFF cells, a similar increase in FN- and DOC-insoluble (P) fraction of FN was observed in
response to both TGF-β1 and TGF-β2 in nonfibroblast MCF10A epithelial cells (Figure 1, C and D, top, –cycloheximide [CHX]). These
findings suggest a rapid response to TGF-β for fibrillogenesis in divergent cell types.
Prior studies in fibroblasts indicated that FN assembly by TGF-β
can occur in the absence of protein synthesis (Allen-Hoffmann et al.,
1988). To examine whether TGF-β stimulated FN assembly within
30 min and was independent of protein synthesis in epithelial
MCF10A cells as well, we investigated FN localization in the presence of CHX, the protein synthesis inhibitor (Figure 1D, bottom, and
Supplemental Figure S1A). CHX treatment did not inhibit TGF-β–
mediated increases in the appearance of FN fibrils (Figure 1D,
+CHX). Consistent with no requirement for new FN synthesis, total
pools of FN did not increase in cells after treatment with TGF-β for
30 min (Figure 1E). TGF-β1– and TGF-β2–induced increase in the
DOC-insoluble (P) fraction of FN in MCF10A epithelial cells also remained high even in the presence of CHX (Supplemental Figure
S1A). These findings indicate that TGF-β–induced fibrillogenesis in
epithelial cells can be protein synthesis independent. We observed
no specific accumulation of cells in any phase of the cell cycle that
could have contributed to fibrillogenesis in response to 30 min of
TGF-β stimulation (Supplemental Figure S1B). To confirm that the
TGF-β–induced fibrils were indeed at the cell surface in MCF10A
cells, we used total internal reflection fluorescence (TIRF) microscopy to image and quantify cell surface FN. In agreement with
Figure 1C, we observed a significant increase in cell surface FN in
response to TGF-β1 and TGF-β2 (Figure 1F). Quantitation of distinct
FN structures on the cell surface was performed using a length of 3
µm as a threshold for cut-off (Coussen et al., 2002; Lutz et al., 2011;
Materials and Methods). This criterion was used in all subsequent
analyses of MCF10A cells. Cells with FN fluorescent puncta less than
the threshold length were classified as cells lacking FN fibrils. This
method of quantification was in accordance with our DOC fractionation observations (Figure 1, A and C), as TGF-β1 and TGF-β2 significantly increased the number of quantifiable FN fibrils compared
with control cells (Figure 1G). To establish firmly that TGF-β was enhancing fibrillogenesis in MCF10A cells, we treated TGF-β–stimulated cells with either the functional upstream domain (FUD) peptide (a short 49-mer that binds the N-terminal sites on FN to block
fibril assembly) or a matched control peptide IIIC (Tomasini-Johansson et al., 2006; Shi et al., 2014) as described in Materials and
Methods. DOC fractionation of the soluble (S) FN and the fibril-associated insoluble pellet (P) FN (Figure 1H) and immunofluorescence (Figure 1I) revealed that the FUD peptide significantly abolished the observed fibril assembly mediated by TGF-β in epithelial
cells compared with either TGF-β alone or TGF-β in the presence of
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a control peptide (Figure 1I and Supplemental Figure S1C)
Given that the immunofluorescence of
FN and DOC fractionation were examined
in nonmigrating cells and the established
role of TGF-β in epithelial cell migration
(Wang et al., 2005; Park and Schwarzbauer,
2014), we next investigated the effect of fibrillogenesis in migrating epithelial cells. To
test this, we carried out a Transwell migration assay for 6 h in the presence of exogenously added rhodamine-FN (Rh-FN;
Materials and Methods). We found that cells
that migrated in the presence of TGF-β
showed distinct Rh-FN fibrils, in contrast to
cells that migrated without TGF-β (Figure
1J). TGF-β–induced fibril formation in migrating cells was disrupted in the presence
of FUD (Shi et al., 2014), indicating that
TGF-β increased FN assembly in migrating
cells as well. Moreover, TGF-β–induced cell
migration was disrupted by the FUD peptide (Figure 1K). The control IIIC peptide did
not affect cell migration (Figure 1K) or fibrillogenesis (Supplemental Figure S1C), consistent with prior reports (Chiang et al.,
2009; Singh and Schwarzbauer, 2014). Together, these data suggest that TGF-β triggers rapid fibrillogenesis in migrating cells
that is independent of new protein
synthesis.

TGF-β type II receptor is required
for fibrillogenesis

FIGURE 1: TGF-β1 and TGF-β2 rapidly increase fibrillogenesis. (A, B) HFFs were treated with
TGF-β1 or TGF-β2 for 30 min and (A) DOC extraction used to fractionate DOC-soluble (S) and
-insoluble (pellet (P)) pool and immunoblotted for FN, or (B) cells were immunostained using
anti-FN. Right, average fibril number (Materials and Methods) in untreated (UN), TGF-β1–, or
TGF-β2–treated cells. Fibril lengths were tracked using the NeuronJ plug-in on ImageJ.
(Materials and Methods). (C) MCF10A cells treated with TGF-β1 or TGF-β2 for 30 min and
processed for DOC extraction and immunoblotted for (S) and (P) FN as in A. (D) MCF10A cells
untreated or treated with 10 ng/ml TGF-β1 or TGF-β2 for 30 min (with or without preincubation
with 20 µg/ml CHX for 2 h) and immunostained for endogenous FN. Right, average fibril number
in untreated (UN), TGF-β1–, or TGF-β2–treated cells. Fibril lengths were tracked using the
NeuronJ plug-in on ImageJ. Scale bar, 5 μm. (E) Total MCF10A cell lysates at the indicated
treatment times were lysed in SDS buffer to solubilize total FN pools ((S) and (P) combined) and
immunoblotted against FN. Vinculin was used as the loading control. (F) Cells treated as in A
and imaged using TIRF microscopy (penetration depth, 110 nm). Scale bar, 5 μm. (G) Average
fibril number analyzed from TIRF images in untreated (UN), TGF-β1–, or TGF-β2–treated cells.
Fibril lengths from F were tracked using the NeuronJ plug-in on ImageJ. (H, I) MCF10A cells
were treated with 10 ng/ml TGF-β1 for 30 min (with or without 500 nM FUD peptide or the
matched control IIIC peptide) and processed either (H) for DOC extraction and immunoblotting
for (S) and (P) FN (actin was the loading control from the soluble pool) or (I) immunostained for
FN. (J) MCF10A cells allowed to migrate for 6 h in the presence of Rh-FN as indicated in the
Volume 28 May 1, 2017

Because TGF-β1 and TGF-β2 treatments
increase fibrillogenesis, we sought to determine whether this was mediated via the
TGF-β receptor serine threonine kinases,
which regulate both SMAD-dependent and
SMAD-independent signaling (Massague,
2012). To test the contribution of the kinase
activity of the type I TGF-β receptor, we
used MCF10A cells and biochemically
quantified the (S) and (P) FN fractions of

figure. Migrated cells are captured by fixing
the cells on the Transwell filter. Images of
Rh-FN are representative of at least four
different fields on the filter from two
independent biological trials. Scale bar, 5 µm.
(K) Transwell migration through FN-coated
Transwells of MCF10A for 12 h either
untreated or in the presence of TGF-β1 alone
or with either control IIIC peptide or FUD
peptide as in J and as indicated. Migrated
cells were counted and plotted relative to
untreated filters. Asterisks indicate significant
differences as indicated (*p < 0.05,
**p < 0.01, ***p < 0.001). Quantitation of
blots is representative of a minimum of three
independent trials.
TβRII in trafficking and fibrillogenesis
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either all three receptors (TβRI, TβRII, and
TβRIII; Mv1Lu), only TβRII and TβRIII (R1b),
or only TβRI and TβRIII (DR; Boyd and
Massague, 1989; Laiho et al., 1990; Wrana
et al., 1992), and qualitatively examined
steady-state fibrillogenesis. Immunolabeling of FN (Figure 2B) revealed that Mv1Lu
and R1b cells showed distinct and punctate
patterns of short FN fibrils, much like untreated MCF10A cells (Figure 1D). DR cells,
which lack TβRII, showed little to no FN fibrils, with only diffuse FN observed (Figure
2B) compared with Mv1Lu cells. Biochemical fractionation of the fibrils showed the
least DOC-insoluble pellet fraction in the
DR cells, with significantly higher amounts
of pellet in the R1b cells that do not express TβRI/ALK5, despite relatively equal
amounts of total FN (Figure 2C, bottom).
All three cell lines expressed the primary
fibronectin receptors integrin α5β1 (Supplemental Figure S2B) and were also reported to express other FN receptors
(Garamszegi et al., 2010). These data suggest that the differences observed could in
part be due to differences in TβRII levels.
To confirm this hypothesis and a role for
TβRII, we transiently suppressed TβRII expression in MCF10A cells using different
short hairpin RNAs (shRNAs) to TβRII
FIGURE 2: TβRII is required for fibrillogenesis. (A) MCF10A cells were preincubated with 3 μM
(shTβRII-1, shTβRII-2, or in combination for
SB431542 for 30 min before treatment with 10 ng/ml TGF-β1 for 30 min. Lysates were DOC
greater knockdown; Figure 2D) and DOCfractionated and immunoblotted for FN. Actin was the loading control for the (S) fraction.
fractionated MCF10A cells to evaluate rela(B, C) Either (B) Mink lung epithelial cells MV1Lu (wild type [WT] for type I, II, III TGF-β
tive (S) and (P) FN fractions (Figure 2E) or
receptors), R1b (WT for type II, III), and DR (WT for type III)) were immunostained for FN or
(C) cell lysates were DOC fractionated and immunoblotted for FN in the soluble (S) and
examine FN by immunolabeling (Figure
insoluble (P) pools. Arrowheads indicate short fibrils and focal contacts. Scale bar, 5 µm.
2F). TGF-β1 was unable to increase the FN
Immunoblot below in C shows total FN levels ((S) and (P) fractions combined) in the Mink lung
in the (P) pool in shTβRII cells compared
cell lines. Vinculin was the loading control. (D) TβRII levels in MCF10A cells transfected with
with shScr cells (Figure 2E) or increase the
shRNAs to TβRII (shTβRII-1 and 2) or shScr to examine efficacy of knockdown. (E) Indicated
appearance of FN fibrils (Figure 2F). QuanMCF10A cells were treated with TGF-β1 (10 ng/ml for 30 min), DOC extracted into the (S) and
titation of fibrils in MCF10A shTβRII-1 and
(P) fractions, and immunoblotted for FN. Numbers for soluble (S) fraction are normalized to actin
2
cells treated with TGF-β revealed a fourand pellet (P) relative to the normalized soluble pool in untreated conditions. Quantitation of
fold decrease in the percentage of cells
blots is representative of three independent trials. (F) Cells transfected with shRNAs to TβRII
containing fibrils compared with control
(shTβRII-1 and 2) or shScr were left untreated or treated with TGF-β1 (10 ng/ml for 30 min) and
cells (N = 200; Figure 2, F and G), in concurimmunostained for FN. Representative images. Scale bar, 3.7 µm. (G) Percentage of fibrilcontaining cells in the indicated conditions were quantified and plotted. Asterisks indicate
rence with the DOC fractionation, indicatsignificant differences (t test) between untreated and TGF-β1–treated samples in shScr
ing a requirement for TβRII in TGF-β–intransfectants (*p < 0.001) and between untreated and TGF-β1–treated samples in shTβRII
duced fibrillogenesis. shScr cells also
(shTβRII-1 and 2) transfectants (*p < 0.001). Data are representative of two independent
exhibited a statistically higher number of
experiments.
cells containing fibrils in untreated conditions compared with shTβRII cells (***p <
untreated and TGF-β–treated cells in the presence of SB431542, a
0.001; Figure 2G). These results and the reduced baseline fibril
type I TGF-β receptor kinase (TβRI/ALK5) inhibitor that blocks
fraction in DR cells (Figure 2, B and C) suggest that fibrillogenesis
SMAD2/3 and SMAD1/5 activation (Supplemental Figure S2A;
requires TβRII.
Daly et al., 2008). We observed an increase in the insoluble (P) fraction in the presence of SB431542 (Figure 2A), indicating that rapid
TβRII’s cytoplasmic domain is required for interactions with
fibrillogenesis is independent of TβRI kinase activity. We previously
integrin α5 and fibrillogenesis
reported that regulation of fibrillogenesis by the TGF-β type III reGiven the central role of integrin α5β1 in fibrillogenesis (Wennerberg
ceptor (TβRIII) depends on the type II TGF-β receptor (TβRII;
et al., 1996; Yang et al., 1999) and the new role for TβRII in fibrilloMythreye et al., 2013). In addition, TβRII is a well-established targenesis (Figure 2), we tested whether TβRII and integrin α5β1 reget of integrin signaling (Galliher and Schiemann, 2007). Hence, to
ceptors act in concert to mediate fibrillogenesis. To determine
test the cellular relevance of TβRI and TβRII to fibrillogenesis, we
whether TβRII interacted with the subunits of the FN receptor (α5β1)
used the mink lung series of epithelial cell lines, which express
at the cell surface, we carried out patch/fluorescence recovery after
1198 | A. Varadaraj et al.
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photobleaching (FRAP) analyses (Henis et al., 1990; Rechtman
et al., 2009) between integrin α5 or β1 and TβRII. This method involves patching and immobilizing one receptor by cross-linking with
a double layer of immunoglobulin Gs (IgGs) and then determining
the effect on the lateral diffusion of a coexpressed membrane protein, which is labeled, immobilized (in this case, by red fluorescent
protein [RFP] or green fluorescent protein [GFP]), and measured by
FRAP (Materials and Methods). Formation of mutual complexes between these proteins can reduce either the mobile fraction (Rf) or
lateral diffusion coefficient (D) of the un-cross-linked protein, depending on the FRAP time scale relative to the rate of dissociation/
association of the oligomer. Complex lifetimes longer than the characteristic FRAP times (stable interactions) result in reduced Rf without affecting D because bleached molecules of the un-cross-linked
protein do not markedly dissociate from the immobile clusters during the FRAP measurements. On the other hand, short complex lifetimes (transient interactions) lead to several association/dissociation
cycles for each fluorescence-labeled molecule during the FRAP
measurement, resulting in lower D without affecting Rf. We coexpressed myc-TβRII and integrin α5-RFP (or β1-GFP) in COS7 cells
and subjected the cells to patch/FRAP measurements with or without IgG cross-linking of myc-TβRII in the presence or absence of FN
(Figure 3A). Integrin α5-RFP expressed alone or with myc-TβRII in
the absence of IgG cross-linking exhibited similar and high lateral
diffusion in the plasma membrane, with a high mobile fraction
(0.91). IgG-mediated patching of myc-TβRII rendered the latter laterally immobile (Figure 3Aiv) and led to a significant reduction in Rf
of integrin α5-RFP (to 0.82; Figure 3Av) without affecting the D values, which were all within the range of 0.1 ± 0.02 μm2/s (unpublished data). Such an effect is characteristic of stable interactions
(Henis et al., 1990; Rechtman et al., 2009) between integrin α5 and
TβRII in a fraction of the total cell surface pool. Incubation with FN
somewhat further reduced the Rf values (a reduction of 0.09–0.13).
However, the additional reduction was mainly due to a marginally
higher Rf value before IgG cross-linking, indicating that steady-state
interactions between TβRII and α5 are not largely increased by the
presence of exogenous FN. Of note, an analogous reduction was
observed in Rf of integrin β1-GFP upon cross-linking of coexpressed
myc-TβRII (Figure 3Avi). The only difference was that, in this case,
addition of FN sufficed to immobilize part of the β1-GFP cell surface
population, possibly due to the multimeric nature of FN, which can
cluster integrin β1 and target it to cytoskeletal structures (McKeownLongo and Mosher, 1984; Bhatia et al., 1999; Eisenberg et al., 2011).
These findings suggest that TβRII interacts stably at the cell surface
with integrin α5β1 and this interaction persists in the presence of
FN. Moreover, the interaction is exclusively with TβRII because similar studies cross-linking the type I TGF-β receptor (myc-TβRI) with
integrin α5-RFP did not affect integrin α5 mobility (Figure 3Avii).
Because the cytoplasmic domain of TβRII is critical for TβRII trafficking (Murphy et al., 2007) and is also a substrate for non–TGF-β
receptor kinases (Galliher and Schiemann, 2007), we tested the role
of the cytoplasmic domain of TβRII in facilitating the interaction
between TβRII and α5. Patch/FRAP analysis of the interactions between myc-TβRII S199, which contains 10 amino acids of the cytoplasmic tail undergoing normal processing and transport to the cell
surface (Ehrlich et al., 2001), and integrin α5-RFP (Figure 3Aviii) revealed that the lateral diffusion of integrin α5-RFP was unaffected
by immobilization of coexpressed TβRII S199, suggesting loss of
TβRII S199 and α5 interaction (Figure 3Aviii). To test whether the
TβRII–integrin α5 interaction mediated by the cytoplasmic domain
influenced fibrillogenesis in MCF10A cells, we first confirmed the
interaction between endogenous TβRII and endogenous α5 using
Volume 28 May 1, 2017

coimmunoprecipitation (Figure 3B). We then examined fibrillogenesis in cells expressing TβRII S199, the complete truncation of the
TβRII cytoplasmic domain (TβRII ∆Cyto) (Siegel et al., 2003), or control pcDNA. We found that both TβRII ∆Cyto– and TβRII S199–expressing MCF10A cells were depleted of fibrils at steady state and
failed to mount an increase in FN fibrils in response to TGF-β1
treatment compared with control (pcDNA) cells (Figure 3C). To investigate whether the kinase activity of TβRII, which is necessary for
optimal internalization (Anders et al., 1998), is required for TGF-β–
induced fibrillogenesis, we used the TβRII point mutant K277R
(TβRIIK277R-HA) and tested interaction with integrin α5 using coimmunoprecipitation. We found that, whereas exogenously expressed TβRII-HA in COS7 cells coimmunoprecipitated integrin α5
(Figure 3D), as observed with endogenous receptors in MCF10A
cells (Figure 3B), TβRIIK277R was less efficient at immunoprecipitating integrin α5, suggesting a requirement for TβRII kinase activity in
the TβRII–integrin α5 interaction. Moreover, similar to the effect of
TβRII S199 and TβRII ∆Cyto, expressing TβRIIK277R in MCF10A
cells resulted in reduced fibrillogenesis in response to TGF-β
(Figure 3E). Taken together, these data suggest that the specific,
stable interaction between integrin α5 and TβRII requires the cytoplasmic domain and kinase activity of TβRII for TGF-β–mediated
fibrillogenesis.

TGF-β increases FN internalization and recycling
for fibrillogenesis
The cytoplasmic domain of TβRII, which is critical for TβRII trafficking (Ehrlich et al., 2001; Rechtman et al., 2009), is also required for
stable interactions with integrin α5 (Figure 3), which can be bound
to FN in early endosome antigen 1 (EEA1)–positive endosomes
and multivesicular endosomes (Lobert et al., 2010). Several studies
indicated that various forms of exogenously added FN are internalized and localized to distinct cellular compartments in fibroblasts
(Sottile and Chandler, 2005; Lobert et al., 2010; Bozavikov et al.,
2014). However, whether FN trafficking is directly required for fibrillogenesis is not known. Given the FN synthesis–independent response to TGF-β–induced fibrillogenesis (Figure 1) and the effect
of the cytoplasmic domain of TβRII, which is critical for TβRII trafficking (Ehrlich et al., 2001; Penheiter et al., 2002; Mitchell et al.,
2004) and now in FN receptor interactions and fibrillogenesis
(Figure 3), we tested whether FN trafficking was required for fibrillogenesis in response to TGF-β. To first investigate whether FN is
internalized to different extents in the presence of TGF-β, we allowed the uptake of Rh-conjugated fibronectin (Rh-FN; Materials
and Methods) for 30 min, followed by acid stripping to remove cell
surface FN, which we confirmed using TIRF microscopy (Supplemental Figure S2C), to retain only the internalized pool of FN. We
observed a twofold increase (*p < 0.05) in the internalized pool of
Rh-FN between untreated and TGF-β1–treated cells and a threefold increase (**p < 0.01) between untreated and TGF-β2–treated
cells within 30 min (Figure 4, A and B). Because exogenous FN
added to FN-null cells was previously shown to be degraded by the
lysosome (Sottile and Chandler, 2005), we tested whether internalized FN in epithelial cells is also degraded in response to a 30-min
TGF-β treatment. Lysosomal protein LAMP1 immunolabeling revealed significant FN exclusion (Figure 4C), suggesting that the
bulk of internalized FN is not localized to the lysosome upon
TGF-β1 and TGF-β2 treatments. In addition, a 6-h lysosomal inhibition with chloroquine (CQ) in TGF-β–treated cells did not significantly increase total FN levels beyond TGF-β–induced FN transcriptional induction (Figure 4D, compare lanes 3 and 4; and 5 and
6), indicating that lysosomal degradation of FN does not occur
TβRII in trafficking and fibrillogenesis
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within 6 h of TGF-β1 or TGF-β2 treatment,
the time period well within nontranscriptional fibrillogenesis (Figure 1).
Given the TGF-β–induced increase in FN
uptake, LAMP1 exclusion of internalized FN,
and rapid increase in fibrillogenesis (Figures
1, A and B, and 4, A and C), we asked
whether internalized FN could contribute directly to matrix-incorporated (DOC-insoluble) (P) FN. To test this, we used biotinylated
FN (FN-biotin) and streptavidin-conjugated
secondary antibody to biochemically quantify only the exogenously added FN-biotin
(Materials and Methods). Because Rh-FN
can be internalized within 30 min (Figure
4A), we allowed uptake of FN-biotin for 30
min, followed by repeated washes to remove unbound FN-biotin from the cell surface. The cells were then allowed to recover
for 1 h in FN-biotin–free medium in the presence of either serum alone (UN), TGF-β1,
or TGF-β2 to test the effect of TGF-β on

FIGURE 3: TβRII’s cytoplasmic domain is required for steady-state interactions with integrin
α5β1 and fibrillogenesis. (A) COS7 cells were cotransfected with expression vectors encoding
myc-TβRII, myc-TβRII S199, or myc-TβRI and integrin α5-RFP or β1-GFP. In control experiments,
the integrin construct was replaced by empty vector. At 48 h after transfection, live cells were
incubated without or with FN and subjected (or not) to IgG-mediated patching/cross-linking of
myc-TβRII or myc-TβRI (Materials and Methods), resulting in Alexa 488 (or 546)–labeled myc–
TGF-β receptor patched and laterally immobile (iv). In control experiments without cross-linking,
the IgG labeling of the myc-TGF-β receptor was replaced by exclusive Fab’ labeling (replacing
the cross-linking IgGs by their respective Fab’ fragments). FRAP studies were conducted on
integrin α5–RFP or β1–GFP at 15°C to minimize internalization. The confocal nature of the FRAP
experimental setup enabled the measurement of integrin fluorescence recovery exclusively at
the plasma membrane (avoiding internal vesicles or ER fluorescence). The laser beam was
focused on the upper cell surface and away from cell edges, thus avoiding focal adhesions. Solid
lines are the best fit of a nonlinear regression analysis to the lateral diffusion equation (Rechtman
et al., 2009). (i) Representative FRAP curve of the lateral diffusion of integrin α5-RFP in a cell
coexpressing myc-TβRII (no IgG cross-linking). (ii) A FRAP curve of integrin α5-RFP in a cell
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coexpressing myc-TβRII immobilized by IgG
cross-linking. (iii) A FRAP curve of the lateral
diffusion of myc-TβRII. (iv) A FRAP curve of
the lateral diffusion of myc-TβRII immobilized
by IgG cross-linking. (v–viii) Average Rf values
derived from multiple patch/FRAP
measurements (coexpressed receptor pairs
are indicated above each graph). Because
the D values were unaffected in all cases
(0.1 ± 0.02 μm2/s), they are not shown. Bars
are mean ± SEM of 30–50 measurements in
each case. Asterisks indicate significant
differences between the Rf values of the pair
indicated by brackets (*p < 0.001; Student’s
t test). (B) MCF10A cells were immuno
precipitated with integrin α5 antibody or IgG
as control and immunoblotted as indicated
for endogenous TβRII and integrin α5. Input
loading control was actin. (C) MCF10A cells
transfected with empty vector or TβRII ∆Cyto
or TβRII S199 were treated with TGFβ1
(10 ng/ml for 30 min) and coimmunostained
using anti-HA (green) to identify transfected
cells and anti-FN to endogenous FN (red).
Scale bar, 5 µm. Quantitation of percentage
of fibril-containing cells (Materials and
Methods) in the indicated conditions; N >
200. (D) COS7 cells transfected for 48 h with
indicated TβRII constructs followed by
immunoprecipitation with anti-α5 antibody
and immunoblotted using either anti-HA or
anti-α5 as indicated. (E) MCF10A cells
transfected with empty vector or TβRII
K277R were treated with TGFβ1 (10 ng/ml
for 30 min) and coimmunostained using
anti-HA (green) to identify transfected cells
and anti-FN to endogenous FN (red). Scale
bar, 4 µm. Quantitation of percentage of
fibril-containing cells (Materials and Methods)
in the indicated conditions; N > 50.
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FIGURE 4: TGF-β increases FN internalization and recycling for fibrillogenesis. (A) Rh-FN at
20 µg/ml was added to MCF10A cells either untreated or in the presence of TGF-β1 and TGF-β2
for 30 min, followed by stripping of cell surface Rh-FN (Materials and Methods). Representative
fluorescence images of Rh-FN. Scale bar, 5 µm. Arrows indicate internalized Rh-FN.
(B) Quantification of integrated fluorescence intensity of Rh-FN normalized to cell area from cells
in A; N > 100/condition. Significance was calculated between untreated samples and TGF-β1–
(*p < 0.05) and TGF-β2–treated (**p < 0.01) samples using the Mann–Whitney U test. Data are
representative of at least three independent experiments. (C) MCF10A cells treated with
TGF-β1/TGF-β2 (10 ng/ml, 30 min) were coimmunostained using anti-LAMP1 and anti-FN;
images acquired using confocal microscopy. Scale bar, 5 µm. (D) MCF10A cells were treated with
TGF-β1 or TGF-β2 for 6 h with or without 100 µM CQ. Lysates were immunoblotted for total FN.
Vinculin was used as loading control. (E) Representative DOC-fractionated biotinylated FN
(FN-biotin; Materials and Methods) in MCF10A cells. FN-biotin at 20 µg/ml was added to cells
for 30 min and washed to remove nonspecific FN-biotin binding on the cell surface. The cells
were then reincubated in FN-biotin–free medium for 1 h with or without TGF-β1 or TGF-β2,
DOC fractionated into (S) and (P) fractions, and immunoblotted using streptavidin-conjugated IR
dye to detect FN-biotin. Actin was used as the loading control for the (S) fraction. Right,
quantitation showing fold difference between the amounts of FN-biotin in the DOC-fractionated
(P) fraction in untreated and TGF-β1– or TGF-β2–treated cells. Data represent quantitation from
two independent experiments. Error bars represent SEM. (F) Schematic of the recycling assay
using Rh-FN upon incubation of cells with 20 µg/ml Rh-FN for 30 min at 37°C in the absence of
TGF-β1 or TGF-β2. Cells are acid stripped to remove surface-bound Rh-FN (Internalized Rh-FN),
followed by reincubation of cells in Rh-FN–free medium at 37°C for 1 h in the presence of
TGF-β1 or TGF-β2. (G) Recycling assay as described in F; left, Rh-FN internalized by cells imaged
after acid stripping using the Epi illumination and TIRF modes (90-nm penetration depth) as
indicated to confirm removal of cell surface Rh-FN. Right, images taken under TIRF mode in
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incorporation of internalized FN-biotin into
a DOC-insoluble (P) fraction. DOC fractionation of the soluble (S) and insoluble (P) fractions revealed that, compared with untreated cells, there was a twofold increase in
the (P) insoluble fraction after TGF-β1 and
TGF-β2 stimulation (compare lanes 2, 4, and
6 in Figure 4E). Because TGF-β treatments
were carried out in the absence of additional
FN-biotin and exogenous FN can be internalized in the presence of TGF-β (Figure 4, A
and B), these data suggest that TGF-β can
increase fibrillogenesis by using an internalized pool of FN-biotin that is recycled to
form fibrils.
To confirm that the insoluble fraction (P)
detected by DOC in the foregoing experiment came from the internalized pool, we
carried out a recycling assay (Figure 4F,
schematic) using labeled Rh-FN, which can
be visualized (Weigert and Donaldson,
2005). Internalization and cell surface removal of Rh-FN was carried out by acid
stripping (Materials and Methods). Images
in the Epi mode versus the TIRF mode confirmed internalized Rh-FN (Figure 4G) because no Rh-FN was observed on TIRF
mode (Figure 4G). These results indicate
that cells internalized Rh-FN within 30 min,
and acid washing of the cells completely
depleted surface Rh-FN. To test our prediction from Figure 4E that TGF-β enhanced
FN recycling, we incubated acid-stripped
cells, which now contained only internalized Rh-FN (Figure 4G, left, MCF10A cells),
with media containing serum (UN), TGF-β1,
or TGF-β2 (Figure 4G and Supplemental
Figure S2D). Compared to untreated cells,
TGF-β1 substantially increased the appearance of Rh-FN at the cell surface after 1 h of
treatment in MCF10A cells (Figure 4G).
This observation was not restricted to epithelial cells because TGF-β1 also induced
recycling of FN to the cell surface in HFF
cells (Figure 4G, right). Similarly, TGF-β2
also increased Rh-FN recycling (Supplemental Figure S2D). These findings lead us
to conclude that TGF-β stimulates internalization and recycling of FN (Figure 4, A and
G) for fibrillogenesis.

either MCF10A or HFF cells, showing the
reappearance of surface FN in cells untreated
or treated with TGF-β1. Images are
representative of at least three independent
trials. Scale bar, 5 µm. Quantitation presented
below was carried out using the 3D object
counter on ImageJ as described in Materials
and Methods after subtracting background
from the cell-free regions. N = 10/condition.
***p < 0.001.
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FIGURE 5: FN recycling and fibrillogenesis require the recycling protein Rab11. (A, B) MCF10A
cells either untreated (serum alone) or treated with TGF-β1/TGF-β2 (10 ng/ml for 30 min) were
coimmunostained using anti-FN and either (A) anti-Arf6 or (B) anti-Rab11 and imaged using
confocal microscopy. Scale bar, 5 µm (main image), 1 µm (inset). Percentage colocalization from A
and B was determined using the Coloc2 plug-in in ImageJ (Materials and Methods) from single
z-plane between FN and either Arf6 or Rab11 in untreated compared with TGF-β1– or TGF-β2–
treated cells. Asterisk indicates significant differences in percentage colocalization (N > 15)
between untreated compared with TGF-β1– or TGF-β2–treated cells (*p < 0.001, t test). Images
are representative of at least three independent experiments. (C) Recycling assay as described in
Figure 4F in the presence of Rh-FN in pEGFP and Rab11 (S25N)-GFP–transfected MCF10A cells.
Cells either untreated (UN) or treated with 10 ng/ml TGF-β1 for 30 min were imaged. Only
constructs expressing EGFP or Rab11(S25N)-GFP (as monitored by GFP expression) were imaged,
and representative images are presented showing abrogated recycling of Rh-FN in Rab11 (S25N)
transfectants. Arrowheads indicate fibrils. Scale bar, 2 µm. (D) MCF10A cells were transfected with
pEGFP or Rab11 (S25N)-GFP as in C, immunostained using anti-FN after treatments with TGF-β1
or TGF-β2 (10 ng/ml for 30 min), and imaged using TIRF microscopy (penetration depth, 110 nm).
Scale bar, 5 µm. (E) Average fibril number/cell analyzed as described in Materials and Methods
from TIRF images in GFP and Rab11 (S25N) mutants in untreated (UN) cells or cells treated with
TGF-β1 or TGF-β2. Fibril lengths were tracked using the NeuronJ plug-in on ImageJ. Asterisk
indicates significant differences (N = 10 [ANOVA]) in fibril number between untreated GFP
transfectants for untreated (UN) cells and cells treated with TGF-β1 or TGF-β2 (*p < 0.001).

Fibrillogenesis requires the recycling protein Rab11
Having observed FN recycling in response to TGF-β for fibrillogenesis (Figure 4), we next investigated the recycling pathways required for fibrillogenesis. Arf6 and Rab11 are two components of
the major recycling pathways, with Rab11 playing roles in both
TβRII and integrin recycling (Mitchell et al., 2004; Kobayashi and
Fukuda, 2013). Specifically, Arf6 colocalizes with inactive integrin
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the recycling protein
fibrillogenesis.

β1, and Rab11 colocalizes with active integrin β1 and specifically regulates trafficking
of the α5β1 heterodimer (Caswell et al.,
2007; Arjonen et al., 2012). To test whether
FN colocalizes with Rab11 or Arf6 in response to TGF-β, we determined the localization of untreated and TGF-β–induced internalized FN pools with components of the
major recycling pathways. We observed no
significant colocalization between FN and
Arf6 in TGF-β1– and TGF-β2–treated cells
compared with untreated cells (Figure 5A).
In contrast, both steady-state and TGF-β–
treated cells showed FN colocalization with
Rab11 (Figure 5B). Moreover, TGF-β1 and
TGF-β2 increased colocalization of FN with
Rab11 by 1.7- and 1.4-fold, respectively
(*p < 0.001; Figure 5B). Not all available FN
was associated with Rab11. It is therefore
possible that a fraction of internalized FN
does not colocalize with Rab11 and may undergo degradation (Sottile and Chandler,
2005; Lobert et al., 2010) or recycle through
alternate modes, including Rab4 (Roberts
et al., 2001).
Owing to the observed colocalization of
FN with Rab11 in response to TGF-β (Figure
5B), we tested whether Rab11 was involved
in FN recycling for fibrils. We carried out the
recycling assay (as described in Figure 4F;
Weigert and Donaldson, 2005) in cells transfected with either GFP or Rab11-S25N, a
dominant-negative Rab11 mutant that fails
to recycle cargo proteins to the plasma
membrane (Ren et al., 1998). Rh-FN was
added to the cells for uptake, acid washed
to remove surface bound Rh-FN, and allowed to recover in medium containing either serum or TGF-β as described in the
schematic in Figure 4F, and the appearance
of the fibrils was determined. In GFP-transfected cells, we observed an increase in
short Rh-FN fibrils in response to TGF-β
(Figure 5C). However, in the Rab11-S25N
transfectants, we observed no appearance
of Rh-FN fibrils (Figure 5C), demonstrating
that Rab11 function is required for TGF-β–
induced rapid FN fibrillogenesis. To confirm
whether Rab11-S25N abolished cell surface
fractions of FN fibrils as seen in Figure 5C,
we used TIRF imaging. We consistently observed significantly fewer cell surface fibrils
in Rab11-S25N transfectants than in control
cells (*p < 0.001; Figure 5, D and E). These
data collectively demonstrate that FN uses
Rab11 to return to the surface for enhanced

DISCUSSION
In this study, we demonstrate a nontranscriptional mechanism by
which TGF-β induces fibrillogenesis via enhanced FN trafficking. We
find rapid fibrillogenesis in response to TGF-β1 and TGF-β2 in both
Molecular Biology of the Cell

fibroblast and epithelial cells. We accomplished this by measuring
incorporation of both exogenous and cell-produced FN into a
DOC-insoluble matrix and visualizing at the cell surface using immunolabeling of FN and TIRF microscopy. Using the 49-mer FUD
peptide to bind N-terminal sites on FN (Tomasini-Johansson et al.,
2006), we efficiently blocked incorporation of FN into the DOC-insoluble pool and fibril appearance induced by TGF-β (Figure 1),
confirming the fibrillar nature of the rapid TGF-β response. TGF-β
plays dominant roles in regulating cell motility and EMT (Wendt
et al., 2012; Morrison et al., 2013), and we find fibrillogenesis in cells
undergoing chemotactic migration (Figure 1J). TGF-β is also a robust inducer of cell motility and invasion in many cell types, including epithelial cells that do not produce significant amounts of fibronectin. However, TGF-β–induced cell migration is indeed repressed
by the fibrillogenesis-blocking FUD peptide. Because our data suggest that TGF-β–induced early fibrillogenesis uses recycled FN
pools (Figures 4 and5) and does not require new protein synthesis
(Figure 1D), we speculate that such rapid changes in the ECM that
precede a transcriptional response are likely to be an important
mechanism for triggering mechanical signals that can potentiate
and sustain TGF-β responses.
We also discovered that TGF-β–induced fibrillogenesis requires
the type II TGF-β receptor, using multiple cell models, including isogenic mink lung cells lacking the TβRII receptor (Laiho et al., 1990;
Figure 2, B and C), and receptor silencing (Figure 2, D–G) in epithelial cells. We also find that TβRII’s cytoplasmic domain is required to
maintain steady-state levels of FN fibrils and is critical for TGF-β induced fibrillogenesis (Figures 2 and 3). Such a requirement may
stem from either the kinase activity of the receptor or loss of interactions with the FN receptor integrin α5β1 mediated via TβRII’s cytoplasmic domain. Indeed, the interaction between integrin α5 and
TβRII is reduced in the K277R mutant of TβRII (Figure 3). TGF-β can
mediate both SMAD and non-SMAD responses, with TβRII phosphorylation by non–TGF-β receptor kinases such as Src being critical
for bridging TGF-β and TβRII to non-SMAD mitogen-activated protein kinase activation (Feng and Derynck, 1996; Derynck and Zhang,
2003; Galliher and Schiemann, 2007). Our data indicate that SMAD
pathways are not involved in the rapid fibrillogenesis response due
to the minor role of TβRI (Figures 2 and 3). These findings indicate
that the initial fibrillogenesis response is a novel non-SMAD outcome and could precede or be required for a longer-term SMAD
response to maintain fibrillogenesis.
Our data from coimmunoprecipitation and PATCH/FRAP experiments show stable cell surface interactions between TβRII and integrins α5 and β1. Whether the activation state of the integrin α5β1
heterodimer dictates the TβRII-integrin interaction remains to be
determined. The interaction between TβRII and integrin α5 appears
to be only marginally increased by FN (Figure 3), suggesting steadystate complexes that are likely to result in constitutive trafficking of
the bound ECM ligand. On the other hand, FN addition was able to
immobilize a subpopulation of integrin β1 without cross-linking of
TβRII. This may reflect fibronectin-mediated clustering of integrin β1
that links it with the cytoskeleton and thus induces partial immobilization (McKeown-Longo and Mosher, 1984; Bhatia et al., 1999).
Whereas TGF-β receptor and integrin trafficking have been separately examined previously (Yao et al., 2002; Caswell et al., 2009),
there is limited knowledge on whether ECM components traffic
along with the receptors. Both integrin α5β1 and TβRII undergo constitutive endocytosis and recycling, with specific endocytosis and
recycling routes influencing either receptor signaling or receptor
turnover (Di Guglielmo et al., 2003; Lobert et al., 2010; Arjonen
et al., 2012). Hence it is likely that ECM deposition may be coordiVolume 28 May 1, 2017

nated/coupled to receptor trafficking. Integrins have, in turn, been
shown to dictate ECM protein endocytosis and turnover (Panetti and
McKeown-Longo, 1993; Shi and Sottile, 2008). However, evidence
on the regulation of ECM traffic by growth factors and its effect on
ECM remodeling is scarce. We find that FN is internalized and recycled in the presence of TGF-β in a TβRII-dependent manner to be
reused to form fibrils (Figure 4). Similarly, our patch/FRAP experiments to measure interactions between the trafficking mutant TβRII
S199 and integrin α5 demonstrate loss of the stable interaction between the two receptors (Figure 3) and less robust fibrils in the TβRII
S199 transfectants (Figure 3). Thus fibrillogenesis requires the TβRII–
integrin α5β1 interaction. It is likely that the dominant-negative effects of TβRII S199 or TβRII ΔCyto affect endogenous TβRII receptor
and/or integrin trafficking and ultimately disrupt fibrillogenesis.
It was shown previously that fibronectin, along with integrin α5,
internalizes and localizes to the lumen of multivesicular endosomes
with EEA1, a prerequisite for integrin sorting and recycling (Lobert
et al., 2010). Our data are the first demonstration of FN recycling after internalization (Figure 4). Whether TGF-β–induced FN trafficking
and recycling occur concomitantly with active or inactive integrins,
with or without TGF-β receptors, is the focus of our ongoing studies
and will include analyzing the role of the catalytically active from of
TβRII (TβRIIP525L; Carcamo et al., 1995), which is also signaling deficient and has altered endocytosis and recycling in a cell type–dependent manner (Anders et al., 1998; Dore et al., 1998, 2001). We anticipate that these future studies will provide insights into TGF-β
receptor– integrin trafficking and their effect on matrix remodeling.
Our observations of FN localization with Rab11, which is increased in the presence of TGF-β (Figure 5) and is required for fibrillogenesis (Figure 5), suggest Rab11 as a recycling route for FN.
However, we cannot completely rule out that a pool of FN may recycle via Rab4, which has been shown to carry αvβ3 (Roberts et al.,
2001). Prior published routes on TβRII and integrin α5β1 trafficking
showing that 1) TGF-β receptor internalized into early endosomes
can recycle via Rab 11(Penheiter et al., 2002; Mitchell et al., 2004)
and 2) integrin internalization via Rab5 endosomes can be recycled
via Rab 11 (Pellinen and Ivaska, 2006; Arjonen et al., 2012), together
with 3) our findings of FN recycling via Rab11 (Figure 5), indicate
that a pool of FN recycles with integrin in a Rab11-dependent manner, possibly along with TβRII. It is also likely that FN, integrin, and
TβRII internalize into early endosomes concomitantly in response to
TGF-β in either a clathrin/dynamin- or caveolin-dependent way. This
is consistent with observations that endocytic trafficking via clathrinmediated endocytosis shifts the fate of TGF-β receptors from lysosomal degradation to prolonged signaling (Penheiter et al., 2002;
Mitchell et al., 2004).
In conclusion, we provided new insights into growth factor–controlled fibrillogenesis and showed, for the first time, that FN can be
rapidly channeled into FN fibrils from available sources of FN within
30 min. Whether this mechanism can complement transcriptionally
induced FN function or exhibit distinct cellular functions remains to
be examined. We anticipate that this nontranscriptional source of
fibrillogenesis might play a significant role in rapid ECM remodeling
and reinforcement of growth factor responses, particularly during
events requiring precise spatial control of fibrillogenesis, with implications for cell migration, wound repair, and fibrosis.

MATERIALS AND METHODS
Cell line and culture conditions
Nontumorigenic MCF10A breast epithelial cells were obtained
from the American Type Culture Collection and cultured in DMEM/
F12 (1:1) with 5% horse serum, epidermal growth factor (20 ng/ml),
TβRII in trafficking and fibrillogenesis
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hydrocortisone (0.5 mg/ml), cholera toxin (100 ng/ml), and insulin
(10 μg/ml). Human foreskin fibroblasts, COS7 cells, and mink lung
epithelial cells MV1Lu, DR, and R1b were cultured in DMEM supplemented with 10% fetal bovine serum (FBS), and glutamine. Cell lines
were maintained in 37°C humidified incubator buffered with 5% CO2.

Antibodies, reagents, and plasmids
Antibodies to FN (sc8422) and TβRII (sc220) were from Santa Cruz
Biotechnology. Rabbit hemagglutinin (HA) tag (C29F4), integrin α5
(4705S), and LAMP1 (D2D11) were from Cell Signaling Technology.
The 9E10 mouse ascites against the myc tag (Evan et al., 1985) was
from Covance Research Products (Denver, PA). Anti-myc IgG and
monovalent Fab’ fragments were prepared from the 9E10 ascites
as described (Henis et al., 1994). Alexa Fluor 488–goat anti-mouse
IgG and Alexa Fluor 546–goat anti mouse F(ab′)2 were from Invitrogen-Molecular Probes (Eugene, OR); fluorescent F(ab′)2 was converted to Fab’ as described (Gilboa et al., 1998). Rab11 (71-5300)
was from Life Technologies, and Integrin α5 (P1D6) for immunoprecipitation was from the Developmental Studies Hybridoma Bank
(University of Iowa, Iowa City, IA). Vinculin (CP74) was from Calbiochem, and β-actin (A2228) was from Sigma-Aldrich. Ligands TGF-β
and FN were from R&D systems. Lipofectamine 2000 (11668019)
was from Life Technologies. Nocodazole (358240100) was from
Fisher, and CHX (94271-5G) was from Amresco. Rh-FN (FNR01
and custom FNR04) and biotinylated FN (FNR03-A) were from
Cytoskeleton. Propidium iodide (537059) was from Calbiochem.
Plasmids expressing GFP-Rab11S25N (Choudhury et al., 2002;
plasmid ID 12678), HA-tagged dynamin K44A (Song et al., 2004;
plasmid ID 34683) and HA-tagged TβRII-∆Cyto (Siegel et al., 2003;
plasmid ID 14051) were obtained from Addgene. The expression
vectors encoding myc-tagged human TβRII, myc-TβRII S199, and
myc-TβRI (in pcDNA3) were previously described (Ehrlich et al.,
2001; Yao et al., 2002). Integrin α5-RFP and integrin β1-GFP were
constructed based on commercially obtained clones of the human
receptors (OriGene); the coding regions were inserted N-terminally
to monomeric RFP (Ehrlich et al., 2004) or enhanced GFP (EGFP)
Clontech) by PCR.

was loaded alongside. This allows the internal comparison of FN
ratios within the sample and between samples.

Transwell migration assay
Fifty thousand MCF10A cells in serum-free medium containing RhFN were seeded in the upper chamber of a Transwell filter. The filter
was coated on both sides with 10 µg/ml FN before the migration
assay, and cells were allowed to migrate toward the lower chamber
containing medium with 10% FBS (chemotactic gradient) for 6 h at
37°C. Cells on the upper surface of the filter were removed, and
only cells on the lower face of the filter were fixed in 4% paraformaldehyde and mounted using mount medium containing 4′6-diamidino-2-phenylindole (DAPI).

Flow cytometry
Approximately 1 million cells were fixed in 70% ethanol and washed
in ice-cold 1% bovine serum albumin (BSA) in PBS. The cell pellet
was resuspended in 2 ml of ice-cold PBS and fixed in 5 ml of 100%
ethanol added dropwise to keep the final ethanol concentration at
70%. After fixing overnight at 20°C, the fixative was removed and
the samples labeled with 10 μg/ml propidium iodide in 0.1% Triton
X-100 with RNase and incubated for 20 min at room temperature.
The samples were filtered and run on a BD LASRII Flow Cytometer.

Immunofluorescence and transfection
Cells were fixed in 4% paraformaldehyde, permeabilized in 0.3%
Triton X-100, and blocked with 1% BSA in PBS. Primary antibody
(1:200) incubation for 1 h was followed by 30 min of incubation
with Dylight 800 conjugate (5151 Cell Signaling Technology). After
washing, cells were stained with DAPI (Roche). Immunostaining of
FN (1:100) to visualize fibrils was carried out by fixing in 4% paraformaldehyde and permeabilized in 0.1% Triton X-100 for 1 min at
4°C. Immunofluorescence imaging and z-stacking were performed
using a Zeiss LSM700 confocal microscope. Transfection using Lipofectamine 2000 was carried out according to manufacturer’s
instructions.

Microscopy
TβRII knockdown
Two different Mission shRNA sequences from Sigma-Aldrich were
used to knock down TβRII levels. shTβRII-1, 5′-CCGGATGGAAGA
CTTTAAGGTATTTCTCGAGAAATACCTTAAAGTCTCCATTTT
TTTG-3′; and shTβRII-2, 5′-CCGGCAATAACAAAGGCGCAAATAAC
TCGAGTTATTTGCGCCTTTGTTATTGTTTTTTG-3′.

Deoxycholate fractionation of FN
Deoxycholate fractionation of FN was carried out according to a
previously published protocol (Sechler et al., 1996). Briefly, cells
were washed in ice-cold phosphate-buffered saline (PBS), followed
by lysate preparation in buffer containing 2% deoxycholate and
0.02 M Tris-HCl, pH 8.8, supplemented with 2 mM phenylmethylsulfonyl fluoride, 2 mM EDTA, 2 mM iodoacetic acid, and
2 mM N-ethylmalemide. Lysis was carried out by passing the lysate
through a 23-gauge syringe needle several times, followed by incubation on a rotor wheel for 30 min. The lysates were centrifuged at
15,000 rpm for 30 min, and the supernatant was transferred to another tube as the soluble fraction. The pellet/insoluble fraction was
resuspended in SDS lysis buffer containing 1% SDS, 25 mM Tris-HCl,
pH 8.0, and protease inhibitors. Lysates containing SDS were heated
for 1 min at 95°C. In deoxycholate fractionation experiments, which
involve the comparison of ratios between samples, the entire pellet
fraction was loaded onto the gel, and 10% of the soluble fraction
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TIRF images were captured using a Leica AM inverted motorized
microscope equipped with a Hamamatsu ImagEM back-thinned
electron-multiplying cooled charge-coupled device camera. FN fibrils were imaged using the TIRF module at laser penetration depth
of 110 or 90 nm as indicated (Leica HCX Plan Apo objective). Immunofluorescence imaging and z-stacking for colocalization analyses were performed using a Zeiss LSM700 confocal microscope.
Wide-field immunofluorescence images were imaged using the
Olympus IX81 microscope connected to an Olympus 1XZ-UCB
camera.

Statistical analyses and quantification
ImageJ was used to quantify pixel intensities of immunoblots. In
Figure 4A, integrated pixel intensities were measured relative to
surface area of the cells, and the data were acquired setting a constant threshold of 43 for all the treatment conditions used. Because intensity values represented continuous data points, we
used the nonparametric Mann-Whitney U test to calculate p value.
Data are representative of multiple experiments. Colocalization
analyses in Figure 5 were calculated from single z-planes from different regions of interest (ROIs) at a Coates significance of 1 and
computed using the Coloc2 plug-in in ImageJ. Student’s t test was
used to calculate p value. At least 50 different ROIs were included
in a single analysis. Plots in Figures 1, 2, and 5 were constructed
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based on the observation that a fibril is considered a single track
of at least 3 µm in length (Coussen et al., 2002; Lutz et al., 2011).
A fibronectin trimer and a pentamer have been shown to form fibril-like structures. The pentamer has a length of 90–100 nm
(Coussen et al., 2002). Because the resolution of our microscope
has a 200-nm limit, this made it unreliable to optically zoom into
images to carry out quantification and analyses. A 3-µm cutoff was
the smallest length that resembled a fibril, as opposed to an aggregate of fibronectin as previously described (Lutz et al., 2011).
Cells containing fibrils of such threshold lengths were counted as
“with fibril” using the Neuron J plug-in on ImageJ and plotted.
Analysis of variance (ANOVA) with Holm–Sidak test was used to
calculate p values. Data are representative of multiple experiments. Quantitation in Figure 4G was carried out using the threedimensional (3D) object counter on ImageJ. We set a grid on the
TIRF images and introduced a size filter of >30 voxels. We picked
the size cut-off based on background Rh signal noise, which was
completely filtered out at >30 in cell free samples. We randomly
analyzed 20 ROIs for 10 cells/condition.
Error bars in all experiments represent SEM.

Rhodamine FN–uptake experiments
This protocol is a modification to the published protocol (Weigert
and Donaldson, 2005). Before measuring the uptake and recycling
of Rh-FN, we serum starved cells for 6 h in medium containing
20 μg/ml CHX. To measure uptake, the cells were incubated in
20 μg/ml Rh-FN in serum-free medium for 30 min at 37°C to allow
incorporation. To measure uptake, the coverslip was repeatedly
washed in PBS, followed by two 30-s washes in acid stripping solution containing 0.5 M NaCl and 0.09 M acetic acid. The coverslips
were rinsed again in ice-cold PBS and fixed for immunostaining. The
efficiency of the acid stripping was determined using TIRF microscopy. To measure recycling, the acid-stripped coverslips were returned to a 37°C incubator in medium containing serum and growth
factors. After 1 h, the coverslips were repeatedly rinsed in PBS and
fixed for immunostaining and visualization. Resurfacing of Rh-FN as
measured by TIRF microscopy (penetration depth, 90 nm) was a
measure of recycled FN, which was detectable only on the TIRF
mode.

2) Alexa Fluor 488 (or 546)–IgG goat anti-mouse (40 μg/ml). This
protocol results in the myc-tagged receptors cross-linking and immobilization by IgGs. In control experiments in which myc-TβRII or
myc-TβRI was not cross-linked, the foregoing IgGs were replaced by
equivalent monovalent Fab’ fragments. The integrin α5–RFP (or integrin β1–GFP) in cells treated as described were subjected to FRAP
and patch/FRAP studies as described earlier (Rechtman et al., 2009).
The FRAP measurements were conducted at 15°C, replacing samples within 20 min to minimize internalization during the measurement. An argon-ion laser beam (Innova 70C; Coherent, Santa Clara,
CA) was focused through a fluorescence microscope (Axioimager.
D1; Carl Zeiss MicroImaging, Jena, Germany) to a Gaussian spot of
0.77 ± 0.03 μm (Plan Apochromat 63×/1.4 numerical aperture oilimmersion objective). After a brief measurement at monitoring intensity (528.7 nm and 1 μW for RFP and 488 nm at similar conditions for
GFP), a 5-mW pulse (20 ms) bleached 60–75% of the fluorescence in
the illuminated region, and fluorescence recovery was followed by
the monitoring beam. Values of D and Rf were extracted from the
FRAP curves by nonlinear regression analysis, fitting to a lateral diffusion process (Rechtman et al., 2009) Patch/FRAP studies were performed similarly, except that IgG-mediated cross-linking/patching of
a myc-tagged TGF-β receptor (described earlier) preceded the measurement (Rechtman et al., 2009). This enables us to determine the
effect of immobilizing one receptor type on the lateral diffusion of
the coexpressed fluorescent protein, allowing identification of complex formation between them and distinction between transient and
stable interactions (Henis et al., 1990; Rechtman et al., 2009).
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Biotinylation assay to measure recycled FN
Before biotinylation, cells were serum starved for 2 h and then incubated with 20 µg/ml biotinylated FN (noncleavable) for 30 min at
37°C in serum-free medium (steady state). The cells were repeatedly
washed in PBS and allowed to recover in biotin-FN free medium for
1 h at 37°C with or without 10 ng/ml TGF-β1 or TGF-β2. The lysates
were DOC extracted into soluble (S) and insoluble (pellet [P]) fractions and immunoblotted using streptavidin-conjugated IR Dye
(926-32230; Li-Cor).

FRAP and patch/FRAP
FRAP and patch/FRAP were performed essentially as described previously (Henis et al., 1990; Rechtman et al., 2009). Briefly, at 48 h
posttransfection, COS7 cells transfected with myc-TβRII, myc-TβRII
S199, or myc-TβRI together with integrin α5-RFP or integrin β1-GFP
were serum starved (30 min, 37°C), washed with cold Hanks’ balanced
salt solution (HBSS) supplemented with 20 mM 4-(2-hydroxyethyl)1-piperazineethanesulfonic acid (HEPES; pH 7.2) and 2% BSA
(Sigma-Aldrich), and blocked with normal goat γ-globulin (200 μg/ml,
30 min, 4°C). They were then labeled successively at 4°C (to avoid
internalization and enable exclusive cell surface labeling) in HBSS/
HEPES/BSA (45-min incubations) with 1) anti-myc IgG (40 μg/ml) and
Volume 28 May 1, 2017

REFERENCES

Abraham LC, Vorrasi J, Kaplan DL (2004). Impact of collagen structure
on matrix trafficking by human fibroblasts. J Biomed Mater Res A 70,
39–48.
Allen-Hoffmann BL, Crankshaw CL, Mosher DF (1988). Transforming growth
factor beta increases cell surface binding and assembly of exogenous
(plasma) fibronectin by normal human fibroblasts. Mol Cell Biol 8,
4234–4242.
Anders RA, Dore JJ Jr, Arline SL, Garamszegi N, Leof EB (1998). Differential requirement for type I and type II transforming growth factor beta
receptor kinase activity in ligand-mediated receptor endocytosis. J Biol
Chem 273, 23118–23125.
Arjonen A, Alanko J, Veltel S, Ivaska J (2012). Distinct recycling of active and
inactive beta1 integrins. Traffic 13, 610–625.
Bhatia R, Munthe HA, Verfaillie CM (1999). Role of abnormal integrincytoskeletal interactions in impaired beta1 integrin function in chronic
myelogenous leukemia hematopoietic progenitors. Exp Hematol 27,
1384–1396.
Bhowmick NA, Zent R, Ghiassi M, McDonnell M, Moses HL (2001). Integrin
beta 1 signaling is necessary for transforming growth factor-beta
activation of p38MAPK and epithelial plasticity. J Biol Chem 276,
46707–46713.
Biname F, Lassus P, Hibner U (2008). Transforming growth factor beta controls the directional migration of hepatocyte cohorts by modulating their
adhesion to fibronectin. Mol Biol Cell 19, 945–956.
TβRII in trafficking and fibrillogenesis

| 1205

Bortell R, Owen TA, Ignotz R, Stein GS, Stein JL (1994). TGF beta 1 prevents
the down-regulation of type I procollagen, fibronectin, and TGF beta 1
gene expression associated with 3T3-L1 pre-adipocyte differentiation. J
Cell Biochem 54, 256–263.
Boyd FT, Massague J (1989). Transforming growth factor-beta inhibition of
epithelial cell proliferation linked to the expression of a 53-kDa membrane receptor. J Biol Chem 264, 2272–2278.
Bozavikov P, Rajshankar D, Lee W, McCulloch CA (2014). Particle size influences fibronectin internalization and degradation by fibroblasts. Exp
Cell Res 328, 172–185.
Carcamo J, Zentella A, Massague J (1995). Disruption of transforming
growth factor beta signaling by a mutation that prevents transphosphorylation within the receptor complex. Mol Cell Biol 15, 1573–1581.
Caswell PT, Spence HJ, Parsons M, White DP, Clark K, Cheng KW, Mills GB,
Humphries MJ, Messent AJ, Anderson KI, et al. (2007). Rab25 associates
with alpha5beta1 integrin to promote invasive migration in 3D microenvironments. Dev Cell 13, 496–510.
Caswell PT, Vadrevu S, Norman JC (2009). Integrins: masters and slaves of
endocytic transport. Nat Rev Mol Cell Biol 10, 843–853.
Chiang HY, Korshunov VA, Serour A, Shi F, Sottile J (2009). Fibronectin is an
important regulator of flow-induced vascular remodeling. Arterioscler
Thromb Vasc Biol 29, 1074–1079.
Choudhury A, Dominguez M, Puri V, Sharma DK, Narita K, Wheatley CL,
Marks DL, Pagano RE (2002). Rab proteins mediate Golgi transport of
caveola-internalized glycosphingolipids and correct lipid trafficking in
Niemann-Pick C cells. J Clin Invest 109, 1541–1550.
Clark K, Pankov R, Travis MA, Askari JA, Mould AP, Craig SE, Newham P,
Yamada KM, Humphries MJ (2005). A specific alpha5beta1-integrin
conformation promotes directional integrin translocation and fibronectin
matrix formation. J Cell Sci 118, 291–300.
Coussen F, Choquet D, Sheetz MP, Erickson HP (2002). Trimers of the
fibronectin cell adhesion domain localize to actin filament bundles and
undergo rearward translocation. J Cell Sci 115, 2581–2590.
Daly AC, Randall RA, Hill CS (2008). Transforming growth factor beta-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel
receptor complexes and is essential for anchorage-independent growth.
Mol Cell Biol 28, 6889–6902.
Danen EH, Sonnenberg A (2003). Integrins in regulation of tissue development and function. J Pathol 201, 632–641.
Danen EH, Sonneveld P, Brakebusch C, Fassler R, Sonnenberg A (2002). The
fibronectin-binding integrins alpha5beta1 and alphavbeta3 differentially
modulate RhoA-GTP loading, organization of cell matrix adhesions, and
fibronectin fibrillogenesis. J Cell Biol 159, 1071–1086.
de Caestecker M (2004). The transforming growth factor-beta superfamily of
receptors. Cytokine Growth Factor Rev 15, 1–11.
Derynck R, Zhang YE (2003). Smad-dependent and Smad-independent
pathways in TGF-beta family signalling. Nature 425, 577–584.
Di Guglielmo GM, Le Roy C, Goodfellow AF, Wrana JL (2003). Distinct
endocytic pathways regulate TGF-beta receptor signalling and turnover.
Nat Cell Biol 5, 410–421.
Dore JJ Jr, Edens M, Garamszegi N, Leof EB (1998). Heteromeric and
homomeric transforming growth factor-beta receptors show distinct
signaling and endocytic responses in epithelial cells. J Biol Chem 273,
31770–31777.
Dore JJ Jr, Yao D, Edens M, Garamszegi N, Sholl EL, Leof EB (2001).
Mechanisms of transforming growth factor-beta receptor endocytosis
and intracellular sorting differ between fibroblasts and epithelial cells.
Mol Biol Cell 12, 675–684.
Ehrlich M, Boll W, Van Oijen A, Hariharan R, Chandran K, Nibert ML,
Kirchhausen T (2004). Endocytosis by random initiation and stabilization
of clathrin-coated pits. Cell 118, 591–605.
Ehrlich M, Shmuely A, Henis YI (2001). A single internalization signal from
the di-leucine family is critical for constitutive endocytosis of the type II
TGF-beta receptor. J Cell Sci 114, 1777–1786.
Eisenberg S, Beckett AJ, Prior IA, Dekker FJ, Hedberg C, Waldmann H,
Ehrlich M, Henis YI (2011). Raft protein clustering alters N-Ras membrane interactions and activation pattern. Mol Cell Biol 31, 3938–3952.
Erickson HP, Carrell N, McDonagh J (1981). Fibronectin molecule visualized in electron microscopy: a long, thin, flexible strand. J Cell Biol 91,
673–678.
Erickson HP, Carrell NA (1983). Fibronectin in extended and compact
conformations. Electron microscopy and sedimentation analysis. J Biol
Chem 258, 14539–14544.
Evan GI, Lewis GK, Ramsay G, Bishop JM (1985). Isolation of monoclonal
antibodies specific for human c-myc proto-oncogene product. Mol Cell
Biol 5, 3610–3616.

1206 | A. Varadaraj et al.

Feng XH, Derynck R (1996). Ligand-independent activation of transforming
growth factor (TGF) beta signaling pathways by heteromeric cytoplasmic
domains of TGF-beta receptors. J Biol Chem 271, 13123–13129.
Galliher AJ, Schiemann WP (2006). Beta3 integrin and Src facilitate
transforming growth factor-beta mediated induction of epithelialmesenchymal transition in mammary epithelial cells. Breast Cancer Res
8, R42.
Galliher AJ, Schiemann WP (2007). Src phosphorylates Tyr284 in TGF-beta
type II receptor and regulates TGF-beta stimulation of p38 MAPK
during breast cancer cell proliferation and invasion. Cancer Res 67,
3752–3758.
Galliher-Beckley AJ, Schiemann WP (2008). Grb2 binding to Tyr284 in
TbetaR-II is essential for mammary tumor growth and metastasis stimulated by TGF-beta. Carcinogenesis 29, 244–251.
Garamszegi N, Garamszegi SP, Samavarchi-Tehrani P, Walford E, Schneiderbauer MM, Wrana JL, Scully SP (2010). Extracellular matrix-induced
transforming growth factor-beta receptor signaling dynamics. Oncogene
29, 2368–2380.
Gilboa L, Wells RG, Lodish HF, Henis YI (1998). Oligomeric structure of type
I and type II transforming growth factor beta receptors: homodimers
form in the ER and persist at the plasma membrane. J Cell Biol 140,
767–777.
Henis YI, Katzir Z, Shia MA, Lodish HF (1990). Oligomeric structure of the
human asialoglycoprotein receptor: nature and stoichiometry of mutual
complexes containing H1 and H2 polypeptides assessed by fluorescence photobleaching recovery. J Cell Biol 111, 1409–1418.
Henis YI, Moustakas A, Lin HY, Lodish HF (1994). The types II and III transforming growth factor-beta receptors form homo-oligomers. J Cell Biol
126, 139–154.
Hocevar BA, Brown TL, Howe PH (1999). TGF-beta induces fibronectin
synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. EMBO J 18, 1345–1356.
Hocevar BA, Howe PH (2000). Analysis of TGF-beta-mediated synthesis of
extracellular matrix components. Methods Mol Biol 142, 55–65.
Huck L, Pontier SM, Zuo DM, Muller WJ (2010). beta1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role
in the metastatic phase of tumor progression. Proc Natl Acad Sci USA
107, 15559–15564.
Ignotz RA, Massague J (1986). Transforming growth factor-beta stimulates
the expression of fibronectin and collagen and their incorporation into
the extracellular matrix. J Biol Chem 261, 4337–4345.
Kobayashi H, Fukuda M (2013). Arf6, Rab11 and transferrin receptor define
distinct populations of recycling endosomes. Commun Integr Biol 6,
e25036.
Laiho M, Weis MB, Massague J (1990). Concomitant loss of transforming
growth factor (TGF)-beta receptor types I and II in TGF-beta-resistant
cell mutants implicates both receptor types in signal transduction. J Biol
Chem 265, 18518–18524.
Lobert VH, Brech A, Pedersen NM, Wesche J, Oppelt A, Malerod L,
Stenmark H (2010). Ubiquitination of alpha 5 beta 1 integrin controls
fibroblast migration through lysosomal degradation of fibronectinintegrin complexes. Dev Cell 19, 148–159.
Lotz MM, Burdsal CA, Erickson HP, McClay DR (1989). Cell adhesion to
fibronectin and tenascin: quantitative measurements of initial binding
and subsequent strengthening response. J Cell Biol 109, 1795–1805.
Lutz R, Pataky K, Gadhari N, Marelli M, Brugger J, Chiquet M (2011). Nanostenciled RGD-gold patterns that inhibit focal contact maturation induce
lamellipodia formation in fibroblasts. PLoS One 6, e25459.
Mao Y, Schwarzbauer JE (2005). Fibronectin fibrillogenesis, a cell-mediated
matrix assembly process. Matrix Biol 24, 389–399.
Massague J (2012). TGFbeta signalling in context. Nat Rev Mol Cell Biol 13,
616–630.
Massague J, Heino J, Laiho M (1991). Mechanisms in TGF-beta action. Ciba
Found Symp 157, 51–59, discussion 59–65.
McKeown-Longo PJ, Mosher DF (1984). Mechanism of formation of disulfide-bonded multimers of plasma fibronectin in cell layers of cultured
human fibroblasts. J Biol Chem 259, 12210–12215.
Mitchell H, Choudhury A, Pagano RE, Leof EB (2004). Ligand-dependent
and -independent transforming growth factor-beta receptor recycling
regulated by clathrin-mediated endocytosis and Rab11. Mol Biol Cell
15, 4166–4178.
Morrison CD, Parvani JG, Schiemann WP (2013). The relevance of the TGFbeta Paradox to EMT-MET programs. Cancer Lett 341, 30–40.
Murphy SJ, Shapira KE, Henis YI, Leof EB (2007). A unique element in the
cytoplasmic tail of the type II transforming growth factor-beta receptor
controls basolateral delivery. Mol Biol Cell 18, 3788–3799.
Molecular Biology of the Cell

Mythreye K, Knelson EH, Gatza CE, Gatza ML, Blobe GC (2013). TbetaRIII/
beta-arrestin2 regulates integrin alpha5beta1 trafficking, function, and
localization in epithelial cells. Oncogene 32, 1416–1427.
Panetti TS, McKeown-Longo PJ (1993). The alpha v beta 5 integrin receptor
regulates receptor-mediated endocytosis of vitronectin. J Biol Chem
268, 11492–11495.
Pankov R, Cukierman E, Katz BZ, Matsumoto K, Lin DC, Lin S, Hahn C,
Yamada KM (2000). Integrin dynamics and matrix assembly: tensindependent translocation of alpha(5)beta(1) integrins promotes early
fibronectin fibrillogenesis. J Cell Biol 148, 1075–1090.
Park J, Schwarzbauer JE (2014). Mammary epithelial cell interactions with
fibronectin stimulate epithelial-mesenchymal transition. Oncogene 33,
1649–1657.
Pellinen T, Ivaska J (2006). Integrin traffic. J Cell Sci 119, 3723–3731.
Penheiter SG, Mitchell H, Garamszegi N, Edens M, Dore JJ Jr, Leof EB
(2002). Internalization-dependent and -independent requirements for
transforming growth factor beta receptor signaling via the Smad pathway. Mol Cell Biol 22, 4750–4759.
Rechtman MM, Nakaryakov A, Shapira KE, Ehrlich M, Henis YI (2009). Different domains regulate homomeric and heteromeric complex formation
among type I and type II transforming growth factor-beta receptors.
J Biol Chem 284, 7843–7852.
Ren M, Xu G, Zeng J, De Lemos-Chiarandini C, Adesnik M, Sabatini DD
(1998). Hydrolysis of GTP on rab11 is required for the direct delivery
of transferrin from the pericentriolar recycling compartment to the cell
surface but not from sorting endosomes. Proc Natl Acad Sci USA 95,
6187–6192.
Roberts CJ, Birkenmeier TM, McQuillan JJ, Akiyama SK, Yamada SS, Chen
WT, Yamada KM, McDonald JA (1988). Transforming growth factor beta
stimulates the expression of fibronectin and of both subunits of the
human fibronectin receptor by cultured human lung fibroblasts. J Biol
Chem 263, 4586–4592.
Roberts M, Barry S, Woods A, van der Sluijs P, Norman J (2001). PDGFregulated rab4-dependent recycling of alphavbeta3 integrin from early
endosomes is necessary for cell adhesion and spreading. Curr Biol 11,
1392–1402.
Ruoslahti E (1984). Fibronectin in cell adhesion and invasion. Cancer Metastasis Rev 3, 43–51.
Sakai T, Larsen M, Yamada KM (2003). Fibronectin requirement in branching
morphogenesis. Nature 423, 876–881.
Saulnier R, Bhardwaj B, Klassen J, Leopold D, Rahimi N, Tremblay E, Mosher
D, Elliott B (1996). Fibronectin fibrils and growth factors stimulate
anchorage-independent growth of a murine mammary carcinoma. Exp
Cell Res 222, 360–369.
Schwarzbauer JE, DeSimone DW (2011). Fibronectins, their fibrillogenesis,
and in vivo functions. Cold Spring Harb Perspect Biol 3, a005041.
Schwarzbauer JE, Sechler JL (1999). Fibronectin fibrillogenesis: a paradigm
for extracellular matrix assembly. Cur Opin Cell Biol 11, 622–627.
Sechler JL, Takada Y, Schwarzbauer JE (1996). Altered rate of fibronectin
matrix assembly by deletion of the first type III repeats. J Cell Biol 134,
573–583.

Volume 28 May 1, 2017

Shi F, Long X, Hendershot A, Miano JM, Sottile J (2014). Fibronectin matrix
polymerization regulates smooth muscle cell phenotype through a Rac1
dependent mechanism. PLoS One 9, e94988.
Shi F, Sottile J (2008). Caveolin-1-dependent beta1 integrin endocytosis is a
critical regulator of fibronectin turnover. J Cell Sci 121, 2360–2371.
Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J (2003). Transforming
growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA
100, 8430–8435.
Singh P, Schwarzbauer JE (2014). Fibronectin matrix assembly is essential for cell condensation during chondrogenesis. J Cell Sci 127,
4420–4428.
Song BD, Yarar D, Schmid SL (2004). An assembly-incompetent mutant establishes a requirement for dynamin self-assembly in clathrin-mediated
endocytosis in vivo. Mol Biol Cell 15, 2243–2252.
Sottile J, Chandler J (2005). Fibronectin matrix turnover occurs through a
caveolin-1-dependent process. Mol Biol Cell 16, 757–768.
Tomasini-Johansson BR, Annis DS, Mosher DF (2006). The N-terminal 70kDa fragment of fibronectin binds to cell surface fibronectin assembly
sites in the absence of intact fibronectin. Matrix Biol 25, 282–293.
Unlu G, Levic DS, Melville DB, Knapik EW (2014). Trafficking mechanisms of
extracellular matrix macromolecules: insights from vertebrate development and human diseases. Int J Biochem Cell Biol 47, 57–67.
Wang SE, Wu FY, Shin I, Qu S, Arteaga CL (2005). Transforming growth
factor β (TGF-β)-Smad target gene protein tyrosine phosphatase
receptor type kappa is required for TGF-β function. Mol Cell Biol 25,
4703–4715.
Weigert R, Donaldson JG (2005). Fluorescent microscopy-based assays to
study the role of Rab22a in clathrin-independent endocytosis. Methods
Enzymol 403, 243–253.
Wendt MK, Tian M, Schiemann WP (2012). Deconstructing the mechanisms
and consequences of TGF-beta-induced EMT during cancer progression. Cell Tissue Res 347, 85–101.
Wennerberg K, Lohikangas L, Gullberg D, Pfaff M, Johansson S, Fassler R
(1996). Beta 1 integrin-dependent and -independent polymerization of
fibronectin. J Cell Biol 132, 227–238.
Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M, Wang XF,
Massague J (1992). TGF beta signals through a heteromeric protein
kinase receptor complex. Cell 71, 1003–1014.
Wu C, Hughes PE, Ginsberg MH, McDonald JA (1996). Identification of a
new biological function for the integrin alpha v beta 3: initiation of fibronectin matrix assembly. Cell Adhes Commun 4, 149–158.
Yang JT, Bader BL, Kreidberg JA, Ullman-Cullere M, Trevithick JE, Hynes RO
(1999). Overlapping and independent functions of fibronectin receptor
integrins in early mesodermal development. Dev Biol 215, 264–277.
Yang JT, Hynes RO (1996). Fibronectin receptor functions in embryonic cells
deficient in alpha 5 beta 1 integrin can be replaced by alpha V integrins.
Mol Biol Cell 7, 1737–1748.
Yao D, Ehrlich M, Henis YI, Leof EB (2002). Transforming growth factor-beta
receptors interact with AP2 by direct binding to beta2 subunit. Mol Biol
Cell 13, 4001–4012.

TβRII in trafficking and fibrillogenesis

| 1207

